ASH 2018 | Next-generation BTK inhibitor vecabrutinib for CLL avoids resistance mechanism

Stephan Stilgenbauer

Novel agents such as the BTK inhibitor ibrutinib are an excellent addition to the arsenal of treatments against chronic lymphocytic leukemia (CLL); however, patients eventually become refractory. Stephan Stilgenbauer, MD, of the University of Ulm, Ulm, Germany, discusses the investigation of the next-generation BTK inhibitor vecabrutinib, which as a competitive inhibitor should avoid this mechanism of resistance. This interview took place at the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA.

Share this video